deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04614467

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction (FREEDOM)

A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Sponsor: Lisata Therapeutics, Inc.

Conditions Coronary Microvascular Disease Coronary Microvascular Dysfunction Microvascular Coronary Artery Disease
Interventions CLBS16 Placebo
Updated 18 times since 2020 Last updated: Oct 9, 2023 Started: Oct 29, 2020 Primary completion: Sep 28, 2022 Completion: Sep 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

Other terminated trials from Lisata Therapeutics, Inc.

More terminations from Lisata Therapeutics, Inc.

Listed as NCT04614467, this PHASE2 trial focuses on Coronary Microvascular Disease and Coronary Microvascular Dysfunction and remains terminated or withdrawn. Sponsored by Lisata Therapeutics, Inc., it has been updated 18 times since 2020, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Nov 2023 · 8 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Mar 2023 — Nov 2023 [monthly]

    Terminated PHASE2

  5. Nov 2022 — Mar 2023 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 13 earlier versions

  1. Oct 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2022 — Oct 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  5. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  6. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  8. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  9. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  10. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  11. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  12. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  13. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lisata Therapeutics, Inc.
Data source: Lisata Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations